Safety, Tolerability, and Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Among Study Participants With Traumatic Brain Injury: Results From the PRISM-II Open Label Study

PM & R : the Journal of Injury, Function, and Rehabilitation
Flora M HammondAndrea E Formella

Abstract

Dextromethorphan 20 mg / quinidine 10 mg (DM/Q) was approved to treat pseudobulbar affect (PBA) based on phase 3 trials conducted in participants with amyotrophic lateral sclerosis or multiple sclerosis. PRISM II evaluated DM/Q effectiveness, safety, and tolerability for PBA following stroke, dementia, or traumatic brain injury (TBI). To report results from the TBI cohort of PRISM II, including a TBI-specific functional scale. Open-label trial evaluating twice-daily DM/Q over 90 days. Adults (n = 120) with a clinical diagnosis of PBA secondary to nonpenetrating TBI; stable psychiatric medications were allowed. PRISM II was an open-label, 12-week trial enrolling adults with PBA secondary to dementia, stroke, or TBI (NCT01799941). All study participants received DM/Q 20/10 mg twice daily. Study visits occurred at baseline and at day 30 and day 90. 150 U.S. centers. Primary endpoint was change in Center for Neurologic Study-Lability Scale (CNS-LS) score from baseline to day 90. Secondary outcomes included PBA episode count, Clinical and Patient Global Impression of Change (CGI-C; PGI-C), Quality of Life-Visual Analog Scale (QOL-VAS), treatment satisfaction, Neurobehavioral Functioning Inventory (NFI), Patient Health Questionnaire ...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Oct 2, 1993·Lancet·G AndersenJ O Riis
Feb 1, 1996·Archives of Physical Medicine and Rehabilitation·J S KreutzerC D Serio
Aug 1, 1996·Brain Injury : [BI]·G ZeiligJ Karatinos
Jul 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·S R MooreR A Smith
Jan 8, 1999·Acta Psychiatrica Scandinavica·K W BrownB Pentland
Sep 18, 1999·International Journal of Geriatric Psychiatry·A BurnsR Baldwin
Mar 14, 2001·Archives of Physical Medicine and Rehabilitation·K M HallA Cantagallo
Oct 27, 2004·Neurology·B R BrooksUNKNOWN AVP-923 ALS Study Group
Dec 9, 2004·Multiple Sclerosis : Clinical and Laboratory Research·Richard A SmithRonald A Thisted
Dec 24, 2004·The Journal of Neuropsychiatry and Clinical Neurosciences·Amane TatenoRobert G Robinson
Jan 3, 2006·The Journal of Neuropsychiatry and Clinical Neurosciences·Randolph Schiffer, Laura E Pope
Apr 25, 2006·Annals of Neurology·Hillel S PanitchUNKNOWN Psuedobulbar Affect in Multiple Sclerosis Study Group
Jul 4, 2006·CNS Spectrums·Jeffrey L CummingsDaniel Weintraub
Jun 13, 2008·CNS Drugs·Hal S WortzelDavid B Arciniegas
Apr 11, 2009·The Journal of Neuropsychiatry and Clinical Neurosciences·Josef ParviziMario F Mendez
Sep 15, 2010·Annals of Neurology·Erik P PioroUNKNOWN Safety, Tolerability, and Efficacy Results Trial of AVP-923 in PBA Investigators
Jun 11, 2011·Advances in Therapy·Susan S WorkRandall E Kaye
Mar 23, 2013·Neuroscience and Biobehavioral Reviews·Edward C LauterbachPreetha Sharone Kuppuswamy
Feb 18, 2014·The Psychiatric Clinics of North America·David B Arciniegas, Hal S Wortzel
Oct 23, 2014·Neuropsychiatric Disease and Treatment·William EngelmanJames F Malec
Aug 11, 2015·The Journal of Neuropsychiatry and Clinical Neurosciences·Durga RoyVani Rao
Jan 9, 2016·Journal of Rehabilitation Research and Development·Jennifer R FondaCharles Yonan
May 4, 2016·Pharmacology & Therapeutics·Charles P TaylorRae R Matsumoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

Brain Injury & Trauma

brain injury after impact to the head is due to both immediate mechanical effects and delayed responses of neural tissues.